CA2567365A1 - Use of reboxetine for the treatment of pain - Google Patents

Use of reboxetine for the treatment of pain Download PDF

Info

Publication number
CA2567365A1
CA2567365A1 CA002567365A CA2567365A CA2567365A1 CA 2567365 A1 CA2567365 A1 CA 2567365A1 CA 002567365 A CA002567365 A CA 002567365A CA 2567365 A CA2567365 A CA 2567365A CA 2567365 A1 CA2567365 A1 CA 2567365A1
Authority
CA
Canada
Prior art keywords
pain
reboxetine
pharmaceutically acceptable
acceptable salt
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002567365A
Other languages
English (en)
French (fr)
Inventor
Bernadette Hughes
Ian Mckenzie
Malcolm John Stoker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0412878A external-priority patent/GB0412878D0/en
Priority claimed from GB0425061A external-priority patent/GB0425061D0/en
Application filed by Individual filed Critical Individual
Publication of CA2567365A1 publication Critical patent/CA2567365A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA002567365A 2004-06-09 2005-05-27 Use of reboxetine for the treatment of pain Abandoned CA2567365A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0412878A GB0412878D0 (en) 2004-06-09 2004-06-09 Use
GB0412878.1 2004-06-09
US58865204P 2004-07-16 2004-07-16
US60/588,652 2004-07-16
GB0425061.9 2004-11-12
GB0425061A GB0425061D0 (en) 2004-11-12 2004-11-12 Use
US63442704P 2004-12-07 2004-12-07
US60/634,427 2004-12-07
PCT/IB2005/001904 WO2006000903A2 (en) 2004-06-09 2005-05-27 Use of reboxetine for the treatment of pain

Publications (1)

Publication Number Publication Date
CA2567365A1 true CA2567365A1 (en) 2006-01-05

Family

ID=34979099

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002567365A Abandoned CA2567365A1 (en) 2004-06-09 2005-05-27 Use of reboxetine for the treatment of pain

Country Status (12)

Country Link
US (1) US20080261984A1 (https=)
EP (1) EP1763354A2 (https=)
JP (1) JP2008501778A (https=)
KR (1) KR20070029740A (https=)
AU (1) AU2005256944A1 (https=)
BR (1) BRPI0511941A (https=)
CA (1) CA2567365A1 (https=)
IL (1) IL178827A0 (https=)
MX (1) MXPA06014389A (https=)
NO (1) NO20064642L (https=)
RU (1) RU2006143659A (https=)
WO (1) WO2006000903A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233959A1 (en) 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US9345689B2 (en) 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
KR20200144568A (ko) * 2018-04-17 2020-12-29 상하이 통리엔 파마슈티컬 컴퍼니 리미티드 통증 및/또는 발열을 예방 및/또는 치료하는 의약품, 조합 산물 및 그 응용
WO2019222850A1 (en) * 2018-05-23 2019-11-28 Wex Pharmaceuticals Inc. Synergistic tetrodotoxin formulations and methods of treatment for neuropathic pain
WO2019245975A1 (en) * 2018-06-17 2019-12-26 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20190381056A1 (en) * 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
IL282311B2 (en) * 2018-10-15 2025-08-01 Axsome Therapeutics Inc Use of reboxetine to treat narcolepsy
US20240415842A1 (en) * 2019-12-03 2024-12-19 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US422449A (en) * 1890-03-04 Gage for gas-cocks
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6465458B1 (en) * 1999-07-01 2002-10-15 Pharmacia & Upjohn Company Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
SI1196172T1 (sl) * 1999-07-01 2006-06-30 Pharmacia & Upjohn Co Llc (S,S)-reboksetin za zdravljenje kronicne bolecine
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
EP1667686A1 (en) * 2003-09-09 2006-06-14 Pfizer Products Inc. Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
NZ545494A (en) * 2003-09-12 2009-10-30 Pfizer Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors

Also Published As

Publication number Publication date
NO20064642L (no) 2006-11-13
BRPI0511941A (pt) 2008-01-22
KR20070029740A (ko) 2007-03-14
EP1763354A2 (en) 2007-03-21
RU2006143659A (ru) 2008-06-20
US20080261984A1 (en) 2008-10-23
JP2008501778A (ja) 2008-01-24
WO2006000903A3 (en) 2006-06-08
AU2005256944A1 (en) 2006-01-05
MXPA06014389A (es) 2007-02-19
IL178827A0 (en) 2007-03-08
WO2006000903A2 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
MXPA06003157A (es) Combinaciones de ligandos alfa-2-delta e inhibidores de la acetilcolina esterasa.
CA2567365A1 (en) Use of reboxetine for the treatment of pain
CA2443105C (en) Functional role for cannabinoids in autonomic stability during sleep
US20120277319A1 (en) Use of Tapentadol for Inhibiting and/or Treating Depression and Anxiety
US10695432B2 (en) Solid solution compositions and use in severe pain
JP2001510154A (ja) カッパアゴニスト化合物、製剤、ならびにそれらによる掻痒の予防法および治療法
PT1536782E (pt) Combinação sinérgica de um ligando alfa-2-delta e um inibidor pdev para ser utilizada no tratamento da dor
JP2003526594A (ja) カッパ・アゴニスト抗掻痒薬学的製剤およびそれにより掻痒を治療する方法
AU2011200717A1 (en) Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
US20170043016A1 (en) Solid Solution Compositions and Use in Severe Pain
US11918654B2 (en) Solid solution compositions and use in severe pain
RU2011146032A (ru) Соединения-агонисты рецептора 5-ht4 для лечения расстройств познавательной способности
ES2987503T3 (es) Compuestos que tienen afinidad por el receptor de melatonina como agente profiláctico o terapéutico para el delirio confusional
JP2017533956A (ja) 筋肉痛を含む病態の治療のための組合せ
JP2015516452A (ja) （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよび抗けいれん剤を含む医薬組成物
JP6116673B2 (ja) （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよびガバペンチノイドを含む医薬組成物
CN101208095A (zh) 瑞波西汀在治疗疼痛中的应用
KR20250059489A (ko) 조현병 및 기타 신경정신장애 및 신경학적 장애의 치료를 위한 환각물질 포함 조합물
HK1113092A (en) Use of reboxetine for the treatment of pain
CA2338327A1 (en) Use of moclobemide for treating pain and other diseases
CN103153295A (zh) 来氟米特和丙二腈酰胺类似物的新用途
CN114080221A (zh) 用于减轻疼痛的布洛芬与曲马多的组合
TW200523257A (en) Use of organic compounds
WO2010029958A1 (ja) 侵害受容性疼痛の新規治療用医薬組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued